Avexegen


Avexegen
San Diego, CA

Venture-Backed
Avexegen

Avexegen Therapeutics is an early stage development company working on novel and revolutionary therapies for the $10 Billion GI Market.  Our lead drug candidate, Neuregulin-4 (NRG-4), offers a completely new approach to directly heal damaged and inflamed gut tissue in patients with Crohn’s Disease and ulcerative colitis, as well as in premature infants with necrotizing enterocolitis (NEC).